Publications
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
In recent years, the European Medicines Agency (EMA) has introduced several accelerated pathways (APs) to enable earlier access to promising therapies where there is high unmet medical need, particularly in oncology.
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development. Their promise—a single intervention that can arrest or even cure previously intractable diseases—creates both opportunity and pressure for health systems.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Why investigating the economic case for ongoing COVID-19 vaccination matters While public health strategies around COVID-19 have transitioned from a pandemic to an endemic setting, the…
Understanding the preferences of people with acute leukemia for different health outcomes
25 September 2025
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wanted to understand which aspects, or “dimensions”, of health-related quality-of-life are most important to the general public and to persons with acute leukemia.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…
Altering the trajectory of HIV in Europe
22 May 2025
Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the epidemic remains a pressing public health concern in Europe.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.